Serina Therapeutics receives NYSE deficiency notice on equity standards

Serina Therapeutics (SER) received a deficiency notice from the NYSE American stating the company falls below continued listing criteria due to insufficient shareholders’ equity and recent losses. The company reported shareholders’ equity of $1.6M as of September 30, 2025, and recorded losses in three of its four most recent fiscal years. Serina must submit a compliance plan by February 8, detailing actions to regain compliance by July 9, 2027.